Vantis Vascular’s 6-F CrossFast System Receives FDA Clearance 

October 14, 2026—Vantis Vascular announced FDA 510(k) clearance for a new 6-F model of its CrossFast integrated microcatheter advanced delivery system.

Stryker’s LimFlow TADV System Gains Category I CPT Code

October 14, 2026—Stryker Peripheral Vascular announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has approved a new category I CPT code for transcatheter arterialization of deep veins (TADV) using the company’s LimFlow system.

Gore Viabahn VBX Stent Graft Gains FDA Approval for Use in FEVAR and BEVAR

October 14, 2026—Gore & Associates announced FDA approval of an expanded indication for the company’s Viabahn VBX balloon expandable endoprosthesis (VBX stent graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).

InterVene’s Recana Thrombectomy System Studied for Venous ISR and RVO

October 13, 2026—Results from a prospective, multicenter study evaluated the Recana thrombectomy catheter system (InterVene, Inc.) for the treatment of venous in-stent restenosis (ISR) and residual vein obstruction (RVO).

Early Data Presented From Real-World Registry of Medtronic’s Abre Venous Stent System

October 13, 2026—Early 30-day results from a prospective, real-world registry of the Abre venous self-expanding stent system (Medtronic) showed no stent fractures, a 0.7% rate of target lesion revascularization (TLR), and decreased pain among 151 patients treated for venous outflow obstruction.

Thrombolex Device for Mechanically Channeled Thrombolysis Evaluated in RAPID-PE

October 13, 2026—Thrombolex, Inc., announced interim results from the first 150 patients enrolled in its RAPID-PE postmarket study, a prospective, multicenter, single-arm study evaluating on-the-table mechanically channeled thrombolysis using the Thrombolex device for acute intermediate-risk pulmonary embolism (PE).

FDA Clears E2 Hēlo Thrombectomy System and Integrated Blood Return System

October 13, 2026—Endovascular Engineering, Inc. (E2), a developer of technology for venous thromboembolism, announced FDA 510(k) clearance for both the Hēlo thrombectomy system and Hēlo Return, a blood return system.

AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer

October 9, 2026—AngioDynamics, Inc. announced the appointment of Eric Honroth as President, Chief Executive Officer, and a member of the company’s board of directors.